A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

NCT04440059 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenstrom's Macroglobulinemia Recurrent
Waldenstrom's Macroglobulinemia Refractory

Interventions

DRUG: ICP-022

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.